Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: Evidence from the RESTORE trial

British Journal of Ophthalmology

Volumn 96, Issue 5, 2012, Pages 688-693

  Mitchell, Paul ^a   Annemans, Lieven ^b   Gallagher, Meghan ^c   Hasan, Rafiq ^c   Thomas, Simu ^c   Gairy, Kerry ^d   Knudsen, Martin ^e   Onwordi, Henrietta ^e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b GHENT UNIVERSITY   (Belgium)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Horsham Research Centre   (United Kingdom)

^e IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADULT; ARTICLE; BLINDNESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETIC MACULAR EDEMA; DRUG COST; HEALTH CARE COST; HUMAN; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MONOTHERAPY; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SIMULATION; TREATMENT OUTCOME; UNITED KINGDOM; VISUAL ACUITY; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DIABETIC RETINOPATHY; DRUG COSTS; GREAT BRITAIN; HUMANS; LASER COAGULATION; MACULAR EDEMA; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; VISION DISORDERS; VISUAL ACUITY;

EID: 84860218792     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2011-300726     Document Type: Article

References (34)

1. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77.
2. Royal College of Ophthalmologists. Guidelines for Diabetic Retinopathy. London, UK: Royal College of Ophthalmologists, 2005.
3. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376:124-36.
4. Minassian DC, Owens DR, Reidy A. Prevalence of diabetic macular oedema and related health and social care resource use in England. Br J Ophthalmol. Published Online First: 20 May 2011. doi:10.1136/bjo.2011.204040
5. Lanzetta P, van Nuys K, Tran I, et al. The Economic Burden of Diabetic Macular Edema from a U.S. Private Payer Perspective. Fort Lauderdale, FL, USA: Association for Research in Vision and Ophthalmology (ARVO), Poster A370, 2011.
6. Novartis Pharma UK. Lucentis 10 mg/mL Solution for Injection - Summary of Product Characteristics. Frimley, UK: Novartis Pharma UK, 2011.
7. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997;46:1473-80. (Pubitemid 27369086)
8. Collins PD, Connolly DT, Williams TJ. Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. Br J Pharmacol 1993;109:195-9. (Pubitemid 23113822)
9. Funatsu H, Yamashita H, Noma H, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002;133:70-7. (Pubitemid 34076505)
10. Murata T, Ishibashi T, Khalil A, et al. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res 1995;27:48-52.
11. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-25.
12. Lloyd A, Nafees B, Gavriel S, et al. Health utility values associated with diabetic retinopathy. Diabet Med 2008;25:618-24. (Pubitemid 351590891)
13. Brown MM, Brown GC, Sharma S, et al. Utility values and diabetic retinopathy. Am J Ophthalmol 1999;128:324-30. (Pubitemid 29413229)
14. Kind P, Hardman G, Macran S. UK Popul Norms for EQ-5D Discussion Paper 172. 1999.
15. Matza LS, Rousculp MD, Malley K, et al. The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy. Health Qual Life Outcomes 2008;6:95.
16. Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol 2003;87:1201-4. (Pubitemid 37193905)
17. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-6. (Pubitemid 14127838)
18. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102:527-32. (Pubitemid 14127839)
19. Moss SE, Klein R, Klein BE. The incidence of vision loss in a diabetic population. Ophthalmology 1988;95:1340-8.
20. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.
21. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48.
22. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
23. Mulnier HE, Seaman HE, Raleigh VS, et al. Mortality in people with type 2 diabetes in the UK. Diabet Med 2006;23:516-21.
24. Hirai FE, Knudtson MD, Klein BE, et al. Clinically significant macular edema and survival in type 1 and type 2 diabetes. Am J Ophthalmol 2008;145:700-6.
25. National Health Service. NHS Reference Costs 2008-09. London, UK: Department of Health, National Health Service, 2010.
26. Curtis L. Unit Costs of Health and Social Care. Canterbury, UK: Personal Social Services Research Unit, University of Kent, 2010.
27. Sharma S, Brown GC, Brown MM, et al. The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis. Curr Opin Ophthalmol 2000;11:175-9. (Pubitemid 30341562)
28. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806.
29. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59. (Pubitemid 40022410)
30. Diabetes Control and Complications Trial Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-9.
31. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12. (Pubitemid 30609442)
32. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
33. Bressler NM, Chang TS, Suner IJ, et al. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 2010;117:747-56 e4.
34. Brown MM, Brown GC, Sharma S, et al. Quality of life associated with unilateral and bilateral good vision. Ophthalmology 2001;108:643-7; discussion 647-8.